Portland, OR, Dec. 08, 2022 (GLOBE NEWSWIRE) — According to the report published by Allied Market Research, the global Ovarian Cancer Drugs Market brought in US$2.3 billion in 2021 and is expected to generate US$5.1 billion by 2031, growing at a CAGR of 8.4% from 2022 to 2031. The report offers a comprehensive analysis of changing market dynamics, key segments, value chain, competitive scenario and regional landscape. This research provides valuable guidance to leading players, investors, shareholders and startups in developing strategies for sustainable growth and competitive advantage in the market.
Download free sample report: https://www.alliedmarketresearch.com/request-sample/365
Report coverage and details:
| report coverage | details |
| forecast period | 2022-2031 |
| base year | 2021 |
| Market size in 2021 | $2.3 billion |
| Market size in 2031 | $5.1 billion |
| CAGR | 8.4% |
| Number of pages in the report | 189 |
| segments covered | therapy, distribution channel and region. |
| driver | Global increase in ovarian cancer |
| Increase in the aging population of women | |
| Increase in demand for improved healthcare services | |
| Development of the medical tourism industry in emerging countries | |
| Increasing consumer awareness of health care | |
| Increasing the use of tamoxifen, aromatase inhibitors and PARP inhibitors to treat ovarian cancer | |
| occasions | Accelerated technological advances in drug discovery techniques |
| Heavy government investment in drug development | |
| limitations | The occurrence of several side effects complicates the treatment |
Covid-19 scenario:
- The outbreak of the COVID-19 pandemic negatively impacted key areas of the ovarian cancer drug market due to disruptions in clinical trials and drug supply to patients.
- The pandemic directly impacted the supply of ovarian cancer drugs to cancer patients. Not only has it been difficult to provide chemotherapy and certain other treatments outside of a clinic, the spread of the coronavirus has reduced patients’ willingness and ability to seek treatments and trials for…
[ad_2]
Source story
